JPMorgan Chase & Co. Buys 311,317 Shares of Avanos Medical, Inc. $AVNS

Key Points

• JPMorgan Chase & Co. bought 311,317 shares in the quarter, raising its stake to 577,889 shares (about 1.24% of Avanos) valued at roughly $6.68 million.
• Other institutions also increased positions—most notably Millennium Management (+508% to 547,740 shares)—and institutional investors now own 95.17% of the company's stock.
• Avanos beat the quarter's estimates (EPS $0.29 vs. $0.24) and set FY2026 guidance of $0.90–$1.10 EPS, though analyst sentiment remains mixed with an average MarketBeat rating of "Reduce" and a market cap near $652 million.

JPMorgan Chase & Co. lifted its stake in shares of Avanos Medical, Inc. (NYSE:AVNS - Free Report) by 116.8% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 577,889 shares of the company's stock after buying an additional 311,317 shares during the quarter. JPMorgan Chase & Co. owned about 1.24% of Avanos Medical worth $6,680,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. AQR Capital Management LLC raised its holdings in Avanos Medical by 46.4% in the 1st quarter. AQR Capital Management LLC now owns 192,864 shares of the company's stock valued at $2,700,000 after acquiring an additional 61,095 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Avanos Medical by 4.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,955 shares of the company's stock worth $386,000 after acquiring an additional 1,121 shares during the period. Millennium Management LLC grew its position in shares of Avanos Medical by 508.3% in the first quarter. Millennium Management LLC now owns 547,740 shares of the company's stock valued at $7,849,000 after purchasing an additional 457,703 shares during the last quarter. Empowered Funds LLC increased its stake in shares of Avanos Medical by 5.4% during the first quarter. Empowered Funds LLC now owns 162,182 shares of the company's stock worth $2,324,000 after purchasing an additional 8,348 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Avanos Medical by 17.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 140,810 shares of the company's stock worth $2,018,000 after purchasing an additional 20,541 shares during the period. Institutional investors own 95.17% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on AVNS shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Avanos Medical in a report on Monday, December 22nd. Wall Street Zen upgraded shares of Avanos Medical from a "hold" rating to a "buy" rating in a research note on Saturday. Finally, Zacks Research raised shares of Avanos Medical from a "strong sell" rating to a "hold" rating in a research report on Monday, January 26th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Avanos Medical presently has an average rating of "Reduce".

Avanos Medical Trading Up 2.0%

Shares of AVNS stock opened at $14.01 on Wednesday. Avanos Medical, Inc. has a fifty-two week low of $9.30 and a fifty-two week high of $15.68. The stock's fifty day moving average price is $13.88 and its two-hundred day moving average price is $12.39. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.26 and a current ratio of 2.15. The company has a market cap of $651.65 million, a PE ratio of -8.87 and a beta of 1.07.

Avanos Medical (NYSE:AVNS - Get Free Report) last released its earnings results on Tuesday, February 24th. The company reported $0.29 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.24 by $0.05. The firm had revenue of $180.90 million for the quarter, compared to analysts' expectations of $174.70 million. Avanos Medical had a positive return on equity of 5.47% and a negative net margin of 10.40%.The business's revenue for the quarter was up .7% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.43 earnings per share. Avanos Medical has set its FY 2026 guidance at 0.900-1.100 EPS. Equities analysts predict that Avanos Medical, Inc. will post 1.32 EPS for the current fiscal year.

Avanos Medical Company Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company's products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.